Characteristics of patients with new-onset diabetes
| . | 2018 . | 2019 . | 2020 . | P value . |
|---|---|---|---|---|
| Age, years (mean ± SD) | 13.5 ± 2.4 | 14.2 ± 2.5 | 14.0 ± 2.6 | 0.3462 |
| HbA1c, % (IQR) | 10.3 (5.0) | 8.3 (5.4) | 10.4 (4.1) | 0.0267 |
| HbA1c, mmol/mol (IQR) | 89 (31) | 67 (36) | 90 (21) | |
| %BMIp95 | 128 ± 31 | 129 ± 28 | 135 ± 31 | 0.2765 |
| Ethnicity, n (%) | 0.0065 | |||
| Latinx | 36 (82) | 44 (67) | 45 (55) | |
| Non-Latinx | 7 (16) | 7 (11) | 13 (16) | |
| Unknown | 1 (2) | 15 (22) | 24 (29) | |
| Race, n (%) | NA | |||
| White | 7 (16) | 16 (24) | 15 (18) | |
| Black | 3 (7) | 3 (5) | 7 (9) | |
| Asian | 2 (5) | 2 (3) | 2 (2) | |
| Native American/Eskimo | 0 (0) | 0 (0) | 1 (1) | |
| Other | 31 (70) | 35 (53) | 47 (57) | |
| Unknown | 1 (2) | 10 (15) | 10 (12) | |
| New-onset patients, n (% female) | 44† (57) | 66 (55) | 82 (46) | NA |
| DKA, n (%) | 4 (9) | 2 (3) | 16 (20) | 0.0290 |
| Severe DKA (DKA/new), n (%) | 0/44 (0) | 0/66 (0) | 2/82 (2) | NA |
| Pancreatic antibody, n (%) | NA | |||
| Positive | 2 (5) | 2(3) | 1 (1) | |
| Negative | 35 (80) | 61(92) | 74 (90) | |
| Not done | 7 (16) | 3(5) | 7 (9) | |
| SARS-CoV2 prevalence in DKA‡ | NA | |||
| SARS-CoV2 PCR+, n (%) | — | — | 0/14 (0) | |
| SARS-CoV2 IgG, n (%) | — | — | 2/6 (33) |
| . | 2018 . | 2019 . | 2020 . | P value . |
|---|---|---|---|---|
| Age, years (mean ± SD) | 13.5 ± 2.4 | 14.2 ± 2.5 | 14.0 ± 2.6 | 0.3462 |
| HbA1c, % (IQR) | 10.3 (5.0) | 8.3 (5.4) | 10.4 (4.1) | 0.0267 |
| HbA1c, mmol/mol (IQR) | 89 (31) | 67 (36) | 90 (21) | |
| %BMIp95 | 128 ± 31 | 129 ± 28 | 135 ± 31 | 0.2765 |
| Ethnicity, n (%) | 0.0065 | |||
| Latinx | 36 (82) | 44 (67) | 45 (55) | |
| Non-Latinx | 7 (16) | 7 (11) | 13 (16) | |
| Unknown | 1 (2) | 15 (22) | 24 (29) | |
| Race, n (%) | NA | |||
| White | 7 (16) | 16 (24) | 15 (18) | |
| Black | 3 (7) | 3 (5) | 7 (9) | |
| Asian | 2 (5) | 2 (3) | 2 (2) | |
| Native American/Eskimo | 0 (0) | 0 (0) | 1 (1) | |
| Other | 31 (70) | 35 (53) | 47 (57) | |
| Unknown | 1 (2) | 10 (15) | 10 (12) | |
| New-onset patients, n (% female) | 44† (57) | 66 (55) | 82 (46) | NA |
| DKA, n (%) | 4 (9) | 2 (3) | 16 (20) | 0.0290 |
| Severe DKA (DKA/new), n (%) | 0/44 (0) | 0/66 (0) | 2/82 (2) | NA |
| Pancreatic antibody, n (%) | NA | |||
| Positive | 2 (5) | 2(3) | 1 (1) | |
| Negative | 35 (80) | 61(92) | 74 (90) | |
| Not done | 7 (16) | 3(5) | 7 (9) | |
| SARS-CoV2 prevalence in DKA‡ | NA | |||
| SARS-CoV2 PCR+, n (%) | — | — | 0/14 (0) | |
| SARS-CoV2 IgG, n (%) | — | — | 2/6 (33) |
Bold P values are statistically significant (P < 0.05). %BMIp95, excess percent of the 95th percentile. NA, not applicable.
No information was available on whether one patient was in DKA at diagnosis.
Only subjects admitted as inpatients to CHLA for DKA were tested.